Kazia Therapeutics Limited American Depositary Shares
KZIA
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Last trade$5.36
Day change-$0.24 (-4.29%)
Day range$5.27 – $5.81
Volume445,991
Market cap$87M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for KZIA.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for KZIA.
Recent news
Company coverage with links to the original publishers.
Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and biotech financial leadership, including previous CFO roles at Cardiff Oncology and Cidara Therapeutics, where he led major pharmaceutical partnerships. His appointment is expected to support Kazia's advancement of its lead asset paxalisib across multiple cancer indications and pipeline development.
The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.
Kazia Therapeutics announced the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The lead candidate MSETC is designed to restore immune signaling in tumors resistant to immunotherapy. Kazia plans to advance the SETDB1 program alongside its PD-L1 degrader platform to IND readiness within 18 months at an estimated cost of $6 million, leveraging shared resources and expecting to qualify for Australian R&D tax incentives.
Kazia Therapeutics announced that its CEO will participate in the J.P. Morgan Healthcare Conference week in San Francisco. The company expects to provide a clinical and translational update before month-end from its Phase 1b trial evaluating paxalisib in advanced triple-negative breast cancer, including additional clinical response observations and expanded biomarker analyses. Kazia also plans to provide the first update on its potential first-in-class PD-L1 protein degrader program.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.